BACKGROUND: Salivary ductal carcinoma is a rare cancer with poor prognosis and limited treatment options. Human epidermal receptor 2 (HER2)-directed treatment has been attempted in HER2-amplified or overexpressed salivary gland malignancies with limited success. METHODS: We report resolution of measurable disease and minimal residual disease in a patient with salivary duct cancer treated with trastuzumab, lapatinib, and bevacizumab, with treatment ongoing for more than 2 years. RESULTS: This treatment has been tolerated well except for grade 2 diarrhea and mucositis, which required a dose reduction of lapatinib to 1000 mg daily. The response observed was achieved in spite of receiving extensive prior therapy, including trastuzumab and/or chemotherapy for 20 months on which his tumors progressed. CONCLUSION: The combination of trastuzumab, lapatinib, and bevacizumab may warrant investigation as a non-cytotoxic alternative for treatment of HER2-amplified or overexpressed salivary duct carcinoma and other HER2-amplified or overexpressed salivary gland tumors, particularly those not responsive to trastuzumab monotherapy.
BACKGROUND:Salivary ductal carcinoma is a rare cancer with poor prognosis and limited treatment options. Human epidermal receptor 2 (HER2)-directed treatment has been attempted in HER2-amplified or overexpressed salivary gland malignancies with limited success. METHODS: We report resolution of measurable disease and minimal residual disease in a patient with salivary duct cancer treated with trastuzumab, lapatinib, and bevacizumab, with treatment ongoing for more than 2 years. RESULTS: This treatment has been tolerated well except for grade 2 diarrhea and mucositis, which required a dose reduction of lapatinib to 1000 mg daily. The response observed was achieved in spite of receiving extensive prior therapy, including trastuzumab and/or chemotherapy for 20 months on which his tumors progressed. CONCLUSION: The combination of trastuzumab, lapatinib, and bevacizumab may warrant investigation as a non-cytotoxic alternative for treatment of HER2-amplified or overexpressed salivary duct carcinoma and other HER2-amplified or overexpressed salivary gland tumors, particularly those not responsive to trastuzumab monotherapy.
Authors: Aleix Prat; Marta Parera; Vicky Reyes; Sergio Peralta; Susana Cedrés; Jordi Andreu; Pere Huguet; Josep Maria del Campo Journal: Head Neck Date: 2008-05 Impact factor: 3.147
Authors: M Scaltriti; C Verma; M Guzman; J Jimenez; J L Parra; K Pedersen; D J Smith; S Landolfi; S Ramon y Cajal; J Arribas; J Baselga Journal: Oncogene Date: 2008-12-08 Impact factor: 9.867
Authors: Giorgio Cornolti; Marco Ungari; Maria Laura Morassi; Fabio Facchetti; Elisa Rossi; Davide Lombardi; Piero Nicolai Journal: Arch Otolaryngol Head Neck Surg Date: 2007-10
Authors: Michelle D Williams; Dianna Roberts; George R Blumenschein; Stephane Temam; Merrill S Kies; David I Rosenthal; Randal S Weber; Adel K El-Naggar Journal: Am J Surg Pathol Date: 2007-11 Impact factor: 6.394
Authors: Robert Haddad; A Dimitrios Colevas; Jeffrey F Krane; Dennis Cooper; Bonnie Glisson; Philip C Amrein; Linda Weeks; Rosemary Costello; Marshall Posner Journal: Oral Oncol Date: 2003-10 Impact factor: 5.337
Authors: Gerald S Falchook; Stacy Moulder; Aung Naing; Jennifer J Wheler; David S Hong; Sarina A Piha-Paul; Apostolia M Tsimberidou; Siqing Fu; Ralph Zinner; Filip Janku; Yunfang Jiang; Mei Huang; Kristin L Parkhurst; Razelle Kurzrock Journal: Invest New Drugs Date: 2014-10-18 Impact factor: 3.850
Authors: Andrew C Birkeland; Megan Yanik; Brittny N Tillman; Megan V Scott; Susan K Foltin; Jacqueline E Mann; Nicole L Michmerhuizen; Megan L Ludwig; Morgan M Sandelski; Christine M Komarck; Thomas E Carey; Mark E P Prince; Carol R Bradford; Jonathan B McHugh; Matthew E Spector; J Chad Brenner Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-06-01 Impact factor: 6.223
Authors: Min Yan; Maria Schwaederle; David Arguello; Sherri Z Millis; Zoran Gatalica; Razelle Kurzrock Journal: Cancer Metastasis Rev Date: 2015-03 Impact factor: 9.264
Authors: Shumei Kato; Sheryl K Elkin; Maria Schwaederle; Brett N Tomson; Teresa Helsten; Jennifer L Carter; Razelle Kurzrock Journal: Oncotarget Date: 2015-09-22